$FBLG News

FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting

FibroBiologics Reports Preclinical Data Showing FSdC Spheroids Best Preserve Disc Height In Rabbit Degenerative Disc Disease Model

FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs

FibroBiologics Says IP Australia Issues Notice Of Acceptance For Australian Patent Application Titled ‘Cellular Blend For The Regeneration Of Chondrocytes Or Cartilage Type Cells’

FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body

EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections

FibroBiologics Files U.S. Patent Application For New Cell-Based Technology Designed To Continuously Produce Peptides Such As GLP-1, GIP and GLP-2 In The Body

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

FibroBiologics Receives European Patent Titled Methods Of Enhancing Fibroblast Therapeutic Activity

Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript

FibroBiologics Completes ATM Private Placement Of 298,508 Shares And Warrants At $1.675 Per Unit To Its Chief Scientific Officer

Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications

FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing

FibroBiologics Secures US Patent For Therapeutic Use Of Fibroblasts For Use In Wound Healing

FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media

FibroBiologics Receives Patent From United States Patent And Trademark Office Titled 'Treatment Of Disc Degenerative Disease And Stimulation Of Proteoglycan Synthesis By Fibroblast Conditioned Media And Formulations Thereof'

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

FibroBiologics Releases Third cGMP CYWC628 Drug Product Batch For Shipment To Australia, Supporting Ongoing Phase 1/2 Diabetic Foot Ulcer Trial

FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia